Biodexa Pharmaceuticals Plc
BDRX
$1.55
-$0.01-0.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -1.59% | 53.06% | |||
| Gross Profit | 1.59% | -53.06% | |||
| SG&A Expenses | -1.59% | -10.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 1.49% | -- | |||
| Total Operating Expenses | -1.59% | 21.55% | |||
| Operating Income | 1.59% | -21.55% | |||
| Income Before Tax | 1.59% | 23.50% | |||
| Income Tax Expenses | 1.60% | -3.17% | |||
| Earnings from Continuing Operations | 1.59% | 24.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.59% | 24.51% | |||
| EBIT | 1.59% | -21.55% | |||
| EBITDA | 1.59% | -22.32% | |||
| EPS Basic | 1.59% | 62.61% | |||
| Normalized Basic EPS | 1.59% | 62.11% | |||
| EPS Diluted | 1.59% | 62.61% | |||
| Normalized Diluted EPS | 1.59% | 62.11% | |||
| Average Basic Shares Outstanding | 0.00% | 101.92% | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||